Oestrogen receptor beta: what it means for patients with breast cancer.
Oestrogen receptor (ER) alpha is a well established prognostic marker in breast cancer, and all patients who are ER alpha positive receive tamoxifen as adjuvant endocrine therapy. Although ER alpha predicts a favourable disease outcome, the usefulness of ER beta as a clinical prognostic marker remains to be defined. Here, we outline the history of both ERs and discuss the implications ER beta has to patients with breast cancer.
Speirs
Valerie
V
Molecular Medicine Unit, University of Leeds, Leeds, UK. v.speors@leeds.ac.uk
Carder
Pauline J
PJ
Lane
Sally
S
Dodwell
David
D
Lansdown
Mark R J
MR
Hanby
Andrew M
AM
D014408:Biomarkers, Tumor / Q000266:history / Q000378:metabolism*; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000378:metabolism; D047629:Estrogen Receptor beta; D005260:Female; D049672:History, 19th Century; D049673:History, 20th Century; D049674:History, 21st Century; D006801:Humans; D007150:Immunohistochemistry; D011379:Prognosis; D020033:Protein Isoforms; D011960:Receptors, Estrogen / Q000266:history / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D014408:Biomarkers, Tumor; D047629:Estrogen Receptor beta; D020033:Protein Isoforms; D011960:Receptors, Estrogen